The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: A phase Ib/II study to evaluate the safety and efficacy of atezolizumab plus bevacizumab as adjuvant therapy following carbon ion radiotherapy in hepatocellular carcinoma (VANGUARD trial).
 
Keisuke Koroki
Honoraria - Chugai Pharma
 
Hirokazu Makishima
No Relationships to Disclose
 
Sadahisa Ogasawara
Honoraria - AstraZeneca/Daiichi Sankyo; Chugai Pharma; Eisai; Merck
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Merck
Research Funding - AstraZeneca; Chugai Pharma; Eisai; Lilly
 
Masaru Wakatsuki
No Relationships to Disclose
 
Asahi Takahashi
No Relationships to Disclose
 
Masanori Inoue
No Relationships to Disclose
 
Masato Nakamura
Employment - Kyorin (I)
Honoraria - Astellas Pharma, Abbvie, KOWA Company
Research Funding - Abbvie (Inst)
 
Naoya Kanogawa
Honoraria - AstraZeneca, Century Medical, ASKA Pharmaceutical, Chugai Pharmaceutical
 
Yoshihito Ozawa
No Relationships to Disclose
 
Yosuke Inaba
No Relationships to Disclose
 
Tomoya Kurokawa
No Relationships to Disclose
 
Tetsuro Isozaki
No Relationships to Disclose
 
Makoto Shinoto
Travel, Accommodations, Expenses - Alfresa Pharma Corporation, Hitachi High-Tech Corporation
 
Masayuki Ohtsuka
Speakers' Bureau - Incyte, AstraZeneca, Viatris, Tsumura, Otsuka Pharmaceutical, Miyarisan, Yakult, Abbvie, Chugai Pharmaceutical, Amco, Astellas, MSD, Nipro, Japan Blood Products Organization
Research Funding - Japan Blood Products Organization, Taiho Pharma, AsahiKasei, Chugai Pharmaceutical, Kaken
 
Tatsuya Ohno
Research Funding - Merck (Inst)
 
Yoshiyuki Ueno
Speakers' Bureau - Eisai, Chugai Pharmaceutical Co., Abbvie Inc,
Research Funding - Abbvie Inc., Eisai,
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte Japan; J-Pharma; MSD; Novartis; Ohara Pharmaceutical; Pfizer; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Delta-Fly Pharma; Eisai; J-Pharma; MSD; OncoTherapy Science
 
Masatoshi Kudo
Honoraria - AstraZeneca; Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai; Roche
Research Funding - Abbvie (Inst); Chugai/Roche (Inst); Eisai (Inst); GE Healthcare (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Hideki Hanaoka
No Relationships to Disclose
 
Hitoshi Ishikawa
No Relationships to Disclose